clinic
proven
effect
antivir
strategi
exist
epidem
coronaviru
diseas
conduct
prospect
random
control
openlabel
multicent
trial
involv
adult
patient
patient
randomli
assign
ratio
receiv
convent
therapi
plu
umifenovir
arbidol
favipiravir
day
follow
day
primari
outcom
clinic
recoveri
rate
day
latenc
relief
pyrexia
cough
rate
auxiliari
oxygen
therapi
aot
noninvas
mechan
ventil
nmv
secondari
outcom
safeti
data
collect
day
epidem
coronaviru
diseas
caus
start
dec
apr
report
confirm
case
across
countri
global
mortal
rate
moment
specif
treatment
exist
standard
practic
care
focu
treat
clinic
symptom
pyrexia
cough
acut
respiratori
distress
syndrom
ard
patient
support
care
fluid
manag
auxiliari
oxygen
therapi
proven
clinic
efficaci
antivir
agent
report
whilst
remdesivir
ribavirin
chloroquin
arbidol
current
clinic
trial
influenza
virus
exhibit
similar
diseas
present
similar
organ
trophism
virus
rna
viru
depend
rnadepend
rna
polymeras
rdrp
replic
rdrp
inhibitor
arbidol
common
name
umifenovir
approv
influenza
russia
china
propos
standard
care
option
mainli
base
mechanismofact
moa
effect
treat
influenzaassoci
pneumonia
favipiravir
antivir
drug
target
rdrp
approv
japan
influenza
ugml
influenza
compar
ugml
arbidol
consid
favipiravir
might
serv
potenti
candid
treat
specif
hypothes
favipiravir
would
superior
arbidol
term
improv
clinic
recoveri
rate
day
allevi
pyrexia
cough
ard
evalu
clinic
efficaci
safeti
favipiravir
versu
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
arbidol
treatment
conduct
prospect
random
control
openlabel
multicent
trial
adult
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
patient
assess
elig
basi
age
year
older
voluntarili
provid
inform
consent
initi
symptom
within
day
diagnos
pneumonia
accord
chines
diagnosi
treatment
protocol
novel
coronaviru
pneumonia
moment
sever
critic
type
elig
patient
exclud
meet
follow
criteria
allerg
favipiravir
arbidol
elev
altast
upper
limit
normal
rang
chronic
liver
diseas
cirrhosi
grade
childpugh
c
severecrit
patient
whose
expect
surviv
time
hour
femal
pregnanc
hiv
infect
consid
unsuit
research
patient
best
interest
written
inform
consent
obtain
patient
author
repres
patient
unabl
write
physic
studi
design
prospect
random
control
openlabel
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
multicent
trial
figur
patient
assess
time
enrol
basic
physic
paramet
bodi
temperatur
chronic
viral
coinfect
hcg
childbear
age
femal
clinic
classif
chest
ct
blood
biochemistri
urinalysi
coagul
function
creactiv
protein
nucleic
acid
addit
detail
protocolsap
clinic
classif
moder
sever
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
critic
patient
perform
accord
chines
guidelin
enrol
blood
biochemistri
urinalysi
coagul
function
creactiv
protein
nucleic
acid
examin
third
day
seventh
day
day
addit
chest
ct
seventh
day
axillari
temperatur
respiratori
rate
oxygen
satur
without
support
oxygen
usag
oxygen
therapi
noninvas
posit
pressur
ventil
nppv
record
daili
followup
repeat
measur
made
least
twice
followup
measur
taken
minut
rest
room
temperatur
advers
event
concomit
medic
observ
primari
outcom
clinic
recoveri
rate
day
begin
treatment
clinic
recoveri
defin
continu
hour
recoveri
bodi
temperatur
respiratori
rate
oxygen
satur
cough
relief
treatment
follow
quantit
criteria
axillari
temperatur
respiratori
frequenc
timesmin
oxygen
satur
without
oxygen
inhal
mild
cough
secondari
outcom
includ
latenc
pyrexia
relief
patient
pyrexia
time
enrol
latenc
cough
relief
patient
moder
sever
cough
time
enrol
rate
aot
nmv
allcaus
mortal
dyspnea
rate
respiratori
failur
defin
spo
without
oxygen
inhal
pao
fio
requir
oxygen
therapi
addit
respiratori
support
rate
patient
need
receiv
intens
care
icu
safeti
outcom
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
includ
advers
event
occur
treatment
prematur
discontinu
limit
knowledg
efficaci
arbidol
assum
clinic
recoveri
rate
day
arbidol
group
superior
clinic
efficaci
favipiravir
expect
least
bilater
ci
differ
clinic
recoveri
rate
experiment
group
control
group
calcul
lower
limit
larger
consid
experiment
group
superior
control
group
log
rank
test
use
compar
recoveri
latenc
two
group
secondari
outcom
student
ttest
wilcoxon
rank
sum
test
ttest
applic
perform
safeti
indic
continu
variabl
wilcoxon
rank
sum
test
use
grade
variabl
frequenc
composit
use
statist
descript
categori
variabl
chisquar
test
fisher
exact
test
use
comparison
group
statist
test
p
bilater
consid
statist
signific
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
total
patient
enrol
took
least
one
dosag
drug
consid
full
analysi
set
fa
figur
fa
set
includ
favipiravir
group
arbidol
group
tabl
main
sign
symptom
enrol
patient
pyrexia
fatigu
dri
cough
myalgia
dyspnea
expector
sore
throat
diarrhea
dizzi
insomnia
conjunct
none
significantli
differ
group
differ
time
onset
patient
symptom
time
treatment
initi
group
neither
nucleic
acid
test
lymphocyt
count
erythrocyt
sediment
rate
creactiv
protein
differ
group
tabl
case
favipiravir
group
arbidol
group
underw
chest
ct
diagnos
pneumonia
accord
diagnost
criteria
overal
signific
differ
basic
characterist
patient
two
group
observ
howev
notic
margin
increas
ratio
sever
critic
patient
favipiravir
group
sever
critic
compar
arbidol
group
fisher
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
group
statist
primari
secondari
outcom
present
tabl
tabl
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
tabl
patient
favipiravir
group
patient
arbidol
group
henc
conclud
secondari
outcom
favipiravir
significantli
shorten
latenc
relief
cough
pyrexia
favipiravir
associ
decreas
rate
aot
nmv
dyspnea
overal
respiratori
failur
rate
icu
admiss
allcaus
mortal
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
trial
detect
incid
antiviralassoci
advers
effect
ae
favipiravir
group
incid
arbidol
group
observ
ae
incid
level
favipiravir
associ
increas
serum
uric
acid
arbidol
group
vs
favipiravir
group
statist
differ
observ
frequenc
abnorm
altast
psychiatr
symptom
reaction
digest
tract
reaction
tabl
advers
reaction
disappear
time
patient
discharg
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
conduct
prospect
multicent
openlabel
random
superior
clinic
trial
hypothes
favipiravir
would
superior
arbidol
term
efficaci
moder
symptom
would
acceler
clinic
recoveri
pyrexia
cough
breath
difficulti
compar
arbidol
combin
tradit
chines
medicin
antivir
drug
common
china
due
tradit
medic
cultur
background
treatment
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
choic
also
antiinfect
immun
regul
play
import
role
treatment
ancillari
treatment
tradit
chines
medicin
antiinfect
immunomodulatori
drug
without
statist
differ
group
tabl
trial
sever
limit
firstli
clinic
proven
effect
antivir
drug
serv
control
arm
although
chines
guidelin
recommend
sever
option
includ
arbidol
rct
result
drug
report
arbidol
wide
use
chines
doctor
begin
stage
epidem
jan
base
vitro
evid
ethic
reason
chose
arbidol
control
arm
secondli
observ
time
frame
limit
due
urgenc
epidem
reason
relaps
includ
nucleic
acid
convers
pyrexia
cough
pneumonia
progress
radiolog
track
perform
discharg
patient
thirdli
inclus
criteria
forc
posit
nucleic
acid
test
necess
accuraci
nucleic
acid
assay
limit
might
due
multipl
reason
includ
previou
treatment
latenc
onset
sampl
method
biolog
specimen
characterist
particular
accuraci
problem
known
issu
among
clinic
practition
across
world
estim
assay
might
sensit
patient
earli
stage
diseas
whilst
contact
histori
clinic
manifest
radiolog
evid
lab
result
includ
leukopenia
lymphopenia
could
confirmatori
nucleicacidneg
pneumonia
patient
chines
guidelin
patient
meet
criteria
consid
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
clinic
confirm
trial
patient
favipiravir
group
arbidol
group
nucleicacidposit
enrol
consid
popul
incid
infect
time
trial
wuhan
consid
probabl
misidentifi
patient
pneumonia
diseas
trial
low
fourthli
protocol
prespecifi
clinic
classif
stratif
factor
ethic
concern
aros
complet
exclud
severecrit
case
potenti
benefici
treatment
addit
complex
diseas
progress
moder
severecrit
possibl
termin
trial
treatment
patient
studi
consid
unaccept
posthoc
analysi
show
treatment
clinic
classif
contribut
significantli
primari
outcom
clinic
recoveri
rate
day
differ
frequenc
severecrit
patient
group
reach
margin
signific
made
import
impact
trial
outcom
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
compar
arbidol
favipiravir
significantli
improv
clinic
recoveri
rate
day
favipiravir
associ
significantli
shorten
latenc
relief
pyrexia
cough
antiviralassoci
advers
effect
favipiravir
mild
manag
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
